An experimental antibiotic called EVG7 has shown promise against gram-positive bacterium Clostridioides difficile. | Drug Discovery And Development ...
A newly developed antibiotic called EVG7 could offer a powerful new way to stop Clostridioides difficile, a dangerous gut bacterium that often returns after treatment. In mouse studies, researchers ...
BOULDER, Colo.--(BUSINESS WIRE)--Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2 clinical trial evaluating CRS3123 in patients with Clostridioides difficile ...
Scientists have identified why some gut microbes successfully stay in the gut after fecal transplants, while others are much more transient. The King's College London discovery could help make the ...
Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial ...
Crestone, Inc. ("Crestone") today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive results from a Phase 2 clinical trial evaluating ...
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting ...
Exploring two complex cases of recurrent C. difficile infections unresponsive to antibiotics and FMT, and how naturopathic interventions supported long-term remission and restored quality of life. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results